407 related articles for article (PubMed ID: 19577286)
1. Defects along the T(H)17 differentiation pathway underlie genetically distinct forms of the hyper IgE syndrome.
Al Khatib S; Keles S; Garcia-Lloret M; Karakoc-Aydiner E; Reisli I; Artac H; Camcioglu Y; Cokugras H; Somer A; Kutukculer N; Yilmaz M; Ikinciogullari A; Yegin O; Yüksek M; Genel F; Kucukosmanoglu E; Baki A; Bahceciler NN; Rambhatla A; Nickerson DW; McGhee S; Barlan IB; Chatila T
J Allergy Clin Immunol; 2009 Aug; 124(2):342-8, 348.e1-5. PubMed ID: 19577286
[TBL] [Abstract][Full Text] [Related]
2. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.
Renner ED; Rylaarsdam S; Anover-Sombke S; Rack AL; Reichenbach J; Carey JC; Zhu Q; Jansson AF; Barboza J; Schimke LF; Leppert MF; Getz MM; Seger RA; Hill HR; Belohradsky BH; Torgerson TR; Ochs HD
J Allergy Clin Immunol; 2008 Jul; 122(1):181-7. PubMed ID: 18602572
[TBL] [Abstract][Full Text] [Related]
3. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome.
Woellner C; Gertz EM; Schäffer AA; Lagos M; Perro M; Glocker EO; Pietrogrande MC; Cossu F; Franco JL; Matamoros N; Pietrucha B; Heropolitańska-Pliszka E; Yeganeh M; Moin M; Español T; Ehl S; Gennery AR; Abinun M; Breborowicz A; Niehues T; Kilic SS; Junker A; Turvey SE; Plebani A; Sánchez B; Garty BZ; Pignata C; Cancrini C; Litzman J; Sanal O; Baumann U; Bacchetta R; Hsu AP; Davis JN; Hammarström L; Davies EG; Eren E; Arkwright PD; Moilanen JS; Viemann D; Khan S; Maródi L; Cant AJ; Freeman AF; Puck JM; Holland SM; Grimbacher B
J Allergy Clin Immunol; 2010 Feb; 125(2):424-432.e8. PubMed ID: 20159255
[TBL] [Abstract][Full Text] [Related]
4. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome.
Milner JD; Brenchley JM; Laurence A; Freeman AF; Hill BJ; Elias KM; Kanno Y; Spalding C; Elloumi HZ; Paulson ML; Davis J; Hsu A; Asher AI; O'Shea J; Holland SM; Paul WE; Douek DC
Nature; 2008 Apr; 452(7188):773-6. PubMed ID: 18337720
[TBL] [Abstract][Full Text] [Related]
5. IFN-beta inhibits human Th17 cell differentiation.
Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
[TBL] [Abstract][Full Text] [Related]
6. Signal transducer and activator of transcription 3 (STAT3) mutations underlying autosomal dominant hyper-IgE syndrome impair human CD8(+) T-cell memory formation and function.
Ives ML; Ma CS; Palendira U; Chan A; Bustamante J; Boisson-Dupuis S; Arkwright PD; Engelhard D; Averbuch D; Magdorf K; Roesler J; Peake J; Wong M; Adelstein S; Choo S; Smart JM; French MA; Fulcher DA; Cook MC; Picard C; Durandy A; Tsumura M; Kobayashi M; Uzel G; Casanova JL; Tangye SG; Deenick EK
J Allergy Clin Immunol; 2013 Aug; 132(2):400-11.e9. PubMed ID: 23830147
[TBL] [Abstract][Full Text] [Related]
7. Genetic origins of hyper-IgE syndrome.
Minegishi Y; Karasuyama H
Curr Allergy Asthma Rep; 2008 Sep; 8(5):386-91. PubMed ID: 18682102
[TBL] [Abstract][Full Text] [Related]
8. Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation.
Siegel AM; Stone KD; Cruse G; Lawrence MG; Olivera A; Jung MY; Barber JS; Freeman AF; Holland SM; O'Brien M; Jones N; Nelson CG; Wisch LB; Kong HH; Desai A; Farber O; Gilfillan AM; Rivera J; Milner JD
J Allergy Clin Immunol; 2013 Dec; 132(6):1388-96. PubMed ID: 24184145
[TBL] [Abstract][Full Text] [Related]
9. SH2-domain mutations in STAT3 in hyper-IgE syndrome patients result in impairment of IL-10 function.
Giacomelli M; Tamassia N; Moratto D; Bertolini P; Ricci G; Bertulli C; Plebani A; Cassatella M; Bazzoni F; Badolato R
Eur J Immunol; 2011 Oct; 41(10):3075-84. PubMed ID: 21792878
[TBL] [Abstract][Full Text] [Related]
10. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome.
Minegishi Y; Saito M; Tsuchiya S; Tsuge I; Takada H; Hara T; Kawamura N; Ariga T; Pasic S; Stojkovic O; Metin A; Karasuyama H
Nature; 2007 Aug; 448(7157):1058-62. PubMed ID: 17676033
[TBL] [Abstract][Full Text] [Related]
11. Key findings to expedite the diagnosis of hyper-IgE syndromes in infants and young children.
Hagl B; Heinz V; Schlesinger A; Spielberger BD; Sawalle-Belohradsky J; Senn-Rauh M; Magg T; Boos AC; Hönig M; Schwarz K; Dückers G; von Bernuth H; Pache C; Karitnig-Weiss C; Belohradsky BH; Frank J; Niehues T; Wahn V; Albert MH; Wollenberg A; Jansson AF; Renner ED
Pediatr Allergy Immunol; 2016 Mar; 27(2):177-84. PubMed ID: 26592211
[TBL] [Abstract][Full Text] [Related]
12. Impaired memory B-cell development and antibody maturation with a skewing toward IgE in patients with STAT3 hyper-IgE syndrome.
van de Veen W; Krätz CE; McKenzie CI; Aui PM; Neumann J; van Noesel CJM; Wirz OF; Hagl B; Kröner C; Spielberger BD; Akdis CA; van Zelm MC; Akdis M; Renner ED
Allergy; 2019 Dec; 74(12):2394-2405. PubMed ID: 31269238
[TBL] [Abstract][Full Text] [Related]
13. Clinical Manifestations and Genetic Analysis of 17 Patients with Autosomal Dominant Hyper-IgE Syndrome in Mainland China: New Reports and a Literature Review.
Wu J; Chen J; Tian ZQ; Zhang H; Gong RL; Chen TX; Hong L
J Clin Immunol; 2017 Feb; 37(2):166-179. PubMed ID: 28197791
[TBL] [Abstract][Full Text] [Related]
14. Clinical Profile of Hyper-IgE Syndrome in India.
Saikia B; Rawat A; Minz RW; Suri D; Pandiarajan V; Jindal A; Sahu S; Karim A; Desai M; Taur PD; Pandrowala A; Gowri V; Madkaikar M; Dalvi A; Yadav RM; Lashkari HP; Raj R; Uppuluri R; Swaminathan VV; Bhattad S; Cyril G; Kumar H; Shukla A; Kalra M; Govindaraj G; Singh S
Front Immunol; 2021; 12():626593. PubMed ID: 33717144
[No Abstract] [Full Text] [Related]
15. Atopic dermatitis, STAT3- and DOCK8-hyper-IgE syndromes differ in IgE-based sensitization pattern.
Boos AC; Hagl B; Schlesinger A; Halm BE; Ballenberger N; Pinarci M; Heinz V; Kreilinger D; Spielberger BD; Schimke-Marques LF; Sawalle-Belohradsky J; Belohradsky BH; Przybilla B; Schaub B; Wollenberg A; Renner ED
Allergy; 2014 Jul; 69(7):943-53. PubMed ID: 24898675
[TBL] [Abstract][Full Text] [Related]
16. The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency.
Engelhardt KR; Gertz ME; Keles S; Schäffer AA; Sigmund EC; Glocker C; Saghafi S; Pourpak Z; Ceja R; Sassi A; Graham LE; Massaad MJ; Mellouli F; Ben-Mustapha I; Khemiri M; Kilic SS; Etzioni A; Freeman AF; Thiel J; Schulze I; Al-Herz W; Metin A; Sanal Ö; Tezcan I; Yeganeh M; Niehues T; Dueckers G; Weinspach S; Patiroglu T; Unal E; Dasouki M; Yilmaz M; Genel F; Aytekin C; Kutukculer N; Somer A; Kilic M; Reisli I; Camcioglu Y; Gennery AR; Cant AJ; Jones A; Gaspar BH; Arkwright PD; Pietrogrande MC; Baz Z; Al-Tamemi S; Lougaris V; Lefranc G; Megarbane A; Boutros J; Galal N; Bejaoui M; Barbouche MR; Geha RS; Chatila TA; Grimbacher B
J Allergy Clin Immunol; 2015 Aug; 136(2):402-12. PubMed ID: 25724123
[TBL] [Abstract][Full Text] [Related]
17. STAT3-Mediated Transcriptional Regulation of Osteopontin in STAT3 Loss-of-Function Related Hyper IgE Syndrome.
Goel S; Sahu S; Minz RW; Singh S; Suri D; Oh YM; Rawat A; Sehgal S; Saikia B
Front Immunol; 2018; 9():1080. PubMed ID: 29868029
[TBL] [Abstract][Full Text] [Related]
18. Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.
Minegishi Y; Karasuyama H
Int Immunol; 2009 Feb; 21(2):105-12. PubMed ID: 19088064
[TBL] [Abstract][Full Text] [Related]
19. The Potential and Limits of Hematopoietic Stem Cell Transplantation for the Treatment of Autosomal Dominant Hyper-IgE Syndrome.
Yanagimachi M; Ohya T; Yokosuka T; Kajiwara R; Tanaka F; Goto H; Takashima T; Morio T; Yokota S
J Clin Immunol; 2016 Jul; 36(5):511-6. PubMed ID: 27091139
[TBL] [Abstract][Full Text] [Related]
20. Hyper-IgE syndrome with a novel STAT3 mutation-a single center study from India.
Saikia B; Suri D; Goel S; Rawat A; Minz RW; Gupta A; Sharma S; Ohara O; Imai K; Nonoyama S; Sehgal S; Singh S
Asian Pac J Allergy Immunol; 2014 Dec; 32(4):321-7. PubMed ID: 25543043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
